EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Preclinical Validation of ZF-148-2 Nanodrug for Breast Cancer: Antitumor Efficacy, Survival Benefit, and Histopathological Safety in the 4T1 Murine Model

Zahra Fakhroueian, Marzieh Eghtedardoost, Alireza Massiha, Fereshteh Abbasvandi

Advances in Nanoparticles · 2026 · 15 (04) · 81-112

DOI: 10.4236/anp.2026.154004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advances in Nanoparticles, 2026. Verfasst von Zahra Fakhroueian und 3 weiteren Autor:innen. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Fakhroueian, Z., Eghtedardoost, M., Massiha, A., & Abbasvandi, F. (2026). Preclinical Validation of ZF-148-2 Nanodrug for Breast Cancer: Antitumor Efficacy, Survival Benefit, and Histopathological Safety in the 4T1 Murine Model. Advances in Nanoparticles, 15(04), 81-112. https://doi.org/10.4236/anp.2026.154004

Vancouver

Fakhroueian Z, Eghtedardoost M, Massiha A, Abbasvandi F. Preclinical Validation of ZF-148-2 Nanodrug for Breast Cancer: Antitumor Efficacy, Survival Benefit, and Histopathological Safety in the 4T1 Murine Model. Advances in Nanoparticles. 2026;15(04):81-112. doi:10.4236/anp.2026.154004

BibTeX
@article{Fakhroueian2026,
  author = {Fakhroueian, Zahra and Eghtedardoost, Marzieh and Massiha, Alireza and Abbasvandi, Fereshteh},
  title = {Preclinical Validation of ZF-148-2 Nanodrug for Breast Cancer: Antitumor Efficacy, Survival Benefit, and Histopathological Safety in the 4T1 Murine Model},
  journal = {Advances in Nanoparticles},
  year = {2026},
  volume = {15},
  number = {04},
  pages = {81--112},
  doi = {10.4236/anp.2026.154004}
}
Kostenlos starten →